Susceptibility to mycobacterial infection in VEXAS syndrome.

UBA1 Non-tuberculous mycobacteria VEXAS syndrome auto-inflammatory syndrome

Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
05 Feb 2024
Historique:
received: 29 11 2023
revised: 10 01 2024
accepted: 24 01 2024
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 5 2 2024
Statut: aheadofprint

Résumé

VEXAS is a recently described acquired auto-inflammatory and hematologic syndrome caused by somatic mutations in UBA1. To date, VEXAS is not a recognized cause of acquired immunodeficiency. Two of our 10 VEXAS patients developed a disseminated Mycobacterium avium infection. To shed light on this observation, we retrospectively studied all patients with disseminated non-tuberculous mycobacterial infections (NTMi) seen at our institution over 13 years. Inclusion criteria were a positive blood/bone marrow culture, or 2 positive cultures from distinct sites, or one positive culture with 2 involved sites. patient 1 presented with fever, rash, orbital cellulitis and lung infiltrates. Patient 2 presented with fever and purpura. In both cases, Mycobacterium avium was identified on bone marrow culture. Twenty cases of disseminated NTMi were reviewed. Among 11 HIV-negative patients, three had chronic immune-mediated disease; three had untreated myeloid neoplasm; two had VEXAS; one had undergone kidney transplantation; one had GATA-2 deficiency; and one had no identified aetiology. None had lymphoid neoplasia or had undergone bone marrow transplantation. HIV-negative cases had higher CD4 counts than HIV-positive patients (median CD4: 515/mm3  vs 38/mm3, p< 0.001). Monocytopenia was present in seven cases. At 2 years, six patients had died, including both VEXAS patients. VEXAS patients have an intrinsic susceptibility to disseminated NTMi, which may result from monocytic dysfunction. NTMi can mimic VEXAS flare. Clinicians should maintain a high suspicion for opportunistic infections before escalating immunosuppressive therapy. Further studies are needed to confirm and better decipher the herein reported observations.

Identifiants

pubmed: 38317027
pii: 7601327
doi: 10.1093/rheumatology/keae087
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Stanislas Riescher (S)

Service de Médecine Interne, CHU de Nantes, Nantes, France.

Raphael Lecomte (R)

Service de Maladies Infectieuses et Tropicales, CHU de Nantes, Nantes, France.

Gwenvael Danic (G)

Service de Médecine Interne, CHU de Nantes, Nantes, France.

Julie Graveleau (J)

Service de Médecine Interne, CHU de Nantes, Nantes, France.

Yannick Le Bris (Y)

Laboratoire d'Hématologie, CHU de Nantes, Nantes, France.

Muriel Hello (M)

Cabinet de Dermatologie, Hôpital Privé du Confluent, Nantes.

Aurélie Guillouzouic (A)

Laboratoire de Mycobactériologie, CHU de Nantes, Nantes, France.

Vianney Guardiolle (V)

Clinique de Données, CHU de Nantes, Nantes, France.

Alice Garnier (A)

Service d'Hématologie Clinique, CHU de Nantes, Nantes, France.

Olivier Grossi (O)

Service de Maladies Infectieuses et Tropicales, Hôpital du Confluent, Nantes, France.

Benjamin Gaborit (B)

Service de Maladies Infectieuses et Tropicales, Hôpital du Confluent, Nantes, France.

Antoine Néel (A)

Service de Médecine Interne, CHU de Nantes, Nantes, France.

Classifications MeSH